Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.
• Age ≥ 18 years
• Histological confirmation of indolent B-cell lymphoma that can include any of the following:
‣ Follicular lymphoma (grade 1 or 2 or 3A)
⁃ Marginal zone lymphoma (nodal or extranodal)
⁃ Follicle center lymphoma
• Any stage disease
• Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3
• Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
• Provide written informed consent
• Ability to complete questionnaire(s) by themselves or with assistance
• Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items
• Confirmation from radiation oncologist of suitability to participate in study